コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 and without pretreatment with enalapril, an angiotensin converting enzyme inhibitor.
2 d were more often on diuretics, digoxin, and angiotensin converting enzyme inhibitors.
3 roteinuric angiotensin receptor blockers and angiotensin-converting enzyme inhibitors.
4 ence to angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors.
5 renal crisis remains poor despite the use of angiotensin-converting enzyme inhibitors.
6 ic actions might only partially be shared by angiotensin-converting enzyme inhibitors.
7 ives (eOC), hormonal replacement therapy, or angiotensin-converting enzyme inhibitors.
8 , 378 (9.2%) were taking azathioprine and an angiotensin-converting enzyme inhibitor, 171 (12.9%) wer
9 et, 53% versus 66%; statins, 40% versus 52%; angiotensin-converting enzyme inhibitors, 20% versus 29%
10 eneral practices in the intervention groups, angiotensin-converting enzyme inhibitors (297 [29%] INT
11 [CI]: 49%-64%) of patients were treated with angiotensin-converting enzyme inhibitors, 34% (95% CI: 2
13 lcium antagonist or beta-blocker followed by angiotensin-converting enzyme inhibitor, a diuretic, or
15 her the anti-fibrotic effects exerted by the angiotensin-converting enzyme inhibitor (ACE-I) perindop
16 hypertensive medications included diuretics, angiotensin-converting enzyme inhibitors (ACE), and beta
17 lled trial planned to evaluate the impact of angiotensin-converting enzyme inhibitors (ACE-i) on the
18 al of the study was to assess the effects of angiotensin-converting enzyme inhibitors (ACE-Is) and an
21 and an angiotensin receptor blocker (ARB) or angiotensin-converting enzyme inhibitor (ACEI) has demon
22 th to 95th percentile) and is prevented with angiotensin-converting enzyme inhibitor (ACEI) monothera
23 unction who were discharged on beta-blocker, angiotensin-converting enzyme inhibitor (ACEI) or angiot
24 ation Trial (BENEDICT), all of whom received angiotensin-converting enzyme inhibitor (ACEI) therapy a
25 with nondiabetic kidney disease benefit from angiotensin-converting enzyme inhibitor (ACEI) therapy w
26 remental cost-effectiveness ratios (ICER) of angiotensin-converting enzyme inhibitor (ACEI), beta-blo
27 ective was to assess the association between angiotensin-converting enzyme inhibitor (ACEI)/angiotens
28 kground drug therapy, that is, high doses of angiotensin-converting enzyme inhibitor (ACEi, or angiot
33 round clinician-directed therapy with either angiotensin-converting enzyme inhibitors (ACEI) or angio
35 re with reduced ejection fraction, including angiotensin-converting enzyme inhibitors (ACEI), angiote
36 eatment doses of beta-blockers, statins, and angiotensin-converting enzyme inhibitors (ACEI)/angioten
37 al trials of antihypertensive therapy (ARBs, angiotensin-converting-enzyme inhibitors [ACEi], beta bl
39 schemic heart disease, the pattern of use of angiotensin-converting enzyme inhibitors (ACEIs) in coro
43 hough several studies have shown that use of angiotensin-converting enzyme inhibitors (ACEIs) potenti
44 e past decade, statins, beta-blockers (BBs), angiotensin-converting enzyme inhibitors (ACEIs), and an
45 ion, that thiazide diuretics are superior to angiotensin-converting enzyme inhibitors (ACEIs), calciu
46 rm use of calcium channel blockers (CCBs) or angiotensin-converting enzyme inhibitors (ACEis), respec
47 variation in blood pressure (BP) response to angiotensin-converting enzyme inhibitors (ACEIs), single
49 dication use (antiplatelet therapy, statins, angiotensin-converting enzyme inhibitors [ACEIs] or angi
50 ondition for which the medication was taken (angiotensin-converting enzyme inhibitors [ACEIs], angiot
51 .50; 95% confidence interval, 0.48-0.52), or angiotensin-converting enzyme inhibitors (adjusted odds
52 but an increased risk was found for users of angiotensin-converting enzyme inhibitors (adjusted OR 1
54 ed, prospective evaluation of the effects of angiotensin-converting enzyme inhibitor and angiotensin
55 2009 and 2010 in appropriate prescription of angiotensin-converting enzyme inhibitor and beta-blocker
57 orrhagic shock, 4) shocked mice treated with angiotensin-converting enzyme inhibitors and a single bo
58 ssessed for each of 6 drug classes: statins, angiotensin-converting enzyme inhibitors and angiotensin
59 e for CKD treatment benefit is strongest for angiotensin-converting enzyme inhibitors and angiotensin
61 found that current guidelines for the use of angiotensin-converting enzyme inhibitors and angiotensin
63 iren exceeded responses seen previously with angiotensin-converting enzyme inhibitors and angiotensin
64 ascular responses exceeding those induced by angiotensin-converting enzyme inhibitors and angiotensin
67 ic, but not asymptomatic, heart failure with angiotensin-converting enzyme inhibitors and beta-blocke
68 -receptor blockers and statins, moderate for angiotensin-converting enzyme inhibitors and beta-blocke
73 n, renal function, medication (beta-blocker, angiotensin converting enzyme inhibitor, and angiotensin
74 antiplatelet, antithrombotic, beta blocker, angiotensin-converting enzyme inhibitor, and statin agen
75 RCTs (100%) of statins, 1 of 1 RCT (100%) of angiotensin-converting enzyme inhibitors, and 1 of 1 RCT
76 he use of thiazide diuretics, beta-blockers, angiotensin-converting enzyme inhibitors, and angiotensi
77 itration of beta-adrenergic blocking agents, angiotensin-converting enzyme inhibitors, and angiotensi
79 nt to that of angiotensin receptor blockers, angiotensin-converting enzyme inhibitors, and diuretics.
80 upporting the use of aspirin, beta-blockers, angiotensin-converting enzyme inhibitors, and lipid-lowe
81 criptions, including aspirin, beta-blockers, angiotensin-converting enzyme inhibitors, and lipid-lowe
82 r disease medicines (aspirin, beta blockers, angiotensin-converting enzyme inhibitors, and statins) i
83 it, the preoperative use of beta-blockers or angiotensin-converting enzyme inhibitors, and the intrao
84 0.8 [95% confidence interval, 0.64-0.98] for angiotensin-converting enzyme inhibitors; and relative r
85 to support initiating drug treatment with an angiotensin-converting enzyme inhibitor, angiotensin rec
86 scharge included the following: medications (angiotensin-converting enzyme inhibitors, angiotensin II
87 ormularies' coverage of 8 treatment classes (angiotensin-converting enzyme inhibitors, angiotensin II
89 atio [UPCR] 500-5000 mg/g) and taking stable angiotensin-converting enzyme inhibitors, angiotensin re
92 g or higher on permitted background drugs of angiotensin-converting enzyme inhibitors, angiotensin-re
93 ential introduction of medications including angiotensin-converting-enzyme inhibitors, angiotensin-re
94 ker contribution from the concomitant use of angiotensin converting enzyme inhibitors/angiotensin rec
95 to receive treatment with a beta-blocker, an angiotensin-converting enzyme inhibitor/angiotensin II r
96 erformance measures (discharge instructions, angiotensin-converting enzyme inhibitor/angiotensin II r
97 nts' baseline characteristics (shock, use of angiotensin-converting enzyme inhibitor/angiotensin II r
98 nary intervention, in-hospital and discharge angiotensin-converting enzyme inhibitor/angiotensin II r
99 B-type natriuretic peptide, pkVO2, NYHA, and angiotensin-converting enzyme inhibitor/angiotensin rece
100 and statins but were less likely to receive angiotensin-converting enzyme inhibitor/angiotensin rece
101 thin 24 hours, (2) aspirin at discharge, (3) angiotensin-converting enzyme inhibitor/angiotensin rece
103 l/L increase, P<0.001; CI: 0.31-0.85), using angiotensin-converting enzyme inhibitor/angiotensin rece
105 445-patient subset received at least 1 GDMT (angiotensin-converting enzyme inhibitor/angiotensin rece
106 Statin use was reported in only 30.5+/-2.5%, angiotensin-converting enzyme inhibitor/angiotensin rece
107 no statistically significant improvements in angiotensin-converting enzyme inhibitor/angiotensin rece
108 icant relationships between discharge use of angiotensin-converting enzyme inhibitor/angiotensin rece
109 s a combination of statin, beta-blocker, and angiotensin-converting enzyme inhibitor/angiotensin rece
110 antiplatelet drug, statin, beta-blocker, and angiotensin-converting enzyme inhibitor/angiotensin rece
111 current smoking, chronic kidney disease, and angiotensin-converting enzyme inhibitors/angiotensin II
112 current smoking, chronic kidney disease, and angiotensin-converting enzyme inhibitors/angiotensin II
113 e of and patient adherence to beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin rec
114 vention with a combination of beta-blockers, angiotensin-converting enzyme inhibitors/angiotensin rec
115 f 85 017 individuals, 55%, 76%, and 61% used angiotensin-converting enzyme inhibitors/angiotensin rec
116 ethnicity, but women were less likely to use angiotensin-converting enzyme inhibitors/angiotensin rec
118 escription rates ranged from 44% to 100% for angiotensin-converting enzyme inhibitors/angiotensin rec
120 .11 (95% confidence interval, 1.08-1.18) for angiotensin-converting enzyme inhibitors/angiotensin rec
122 ficial effects of treatment with statins and angiotensin-converting enzyme inhibitors/angiotensin rec
123 , and 66.4% of the patients were on statins, angiotensin-converting enzyme inhibitors/angiotensin rec
124 ational level, history of eczema, the use of angiotensin-converting enzyme inhibitors/angiotensin rec
125 es were treatment at discharge with statins, angiotensin-converting enzyme inhibitors/angiotensin rec
127 D not taking statins, 5.4 million not taking angiotensin-converting enzyme inhibitors/angiotensin rec
128 versus 57% in rural; P=0.1) and reversed for angiotensin-converting enzyme inhibitors/angiotensin rec
129 , documentation of ejection fraction, use of angiotensin-converting enzyme inhibitors/angiotensin rec
130 and 0.86 (0.74-1.01) in patients on statins, angiotensin-converting enzyme inhibitors/angiotensin rec
131 fills for beta-blockers, antiplatelet drugs, angiotensin-converting enzyme inhibitors/angiotensin-2 r
135 eurohormonal activity (like beta-blockers or angiotensin-converting enzyme inhibitors) are considered
136 leroderma Clinical Trials Consortium confirm angiotensin-converting enzyme inhibitors as first-line t
137 edema, acquired C1 inhibitor deficiency, and angiotensin-converting enzyme inhibitor-associated angio
138 ocked mice treated with ramipril for 7 days (angiotensin-converting enzyme inhibitors) before hemorrh
139 ar complications have also been treated with angiotensin-converting enzyme inhibitors, beta-blockers,
140 d and then subsequently filled prescriptions angiotensin-converting enzyme inhibitors, beta-blockers,
141 that promoted antiplatelet agents, statins, angiotensin-converting enzyme inhibitors, blood pressure
142 y done before and after administration of an angiotensin-converting-enzyme inhibitor, but angiography
143 angiotensin type 1 receptor blocker (ARB) or angiotensin-converting enzyme inhibitor can induce regre
145 , statins, angiotensin II receptor blockers, angiotensin-converting enzyme inhibitors) can modify the
146 o; 10 mg (kg bw)(-1)) plus a low dose of the angiotensin-converting enzyme inhibitor captopril (Cap;
148 ptor blockers losartan and valsartan and the angiotensin-converting enzyme inhibitor captopril on wou
149 ministered either beta-blocker, propranolol, angiotensin converting enzyme inhibitor, captopril, or p
150 o; 10 mg/kg, bw) and given a low dose of the angiotensin-converting enzyme inhibitor, captopril (Cap;
151 wer of DPM, three effect categories, namely, angiotensin-converting enzyme inhibitor, cyclooxygenase
152 ium oxide nanoparticles for the detection of angiotensin-converting enzyme inhibitor drug, captopril,
153 sin inhibitor LCZ696 (400 mg daily) with the angiotensin-converting enzyme inhibitor enalapril (20 mg
154 ejection fraction (HFrEF), compared with the angiotensin-converting enzyme inhibitor enalapril, and i
155 gated the short- and long-term effects of an angiotensin-converting enzyme inhibitor (enalapril) and
156 rebral protection was similar to that of the angiotensin-converting enzyme inhibitor, enalapril, whic
157 g therapy, smoking cessation counseling, and angiotensin-converting enzyme inhibitor for left ventric
158 should include calcium channel blockers and angiotensin-converting enzyme inhibitors for cardiovascu
159 lasses: aspirin, statins, beta-blockers, and angiotensin-converting enzyme inhibitors given to patien
160 ant prevented blood pressure lowering in the angiotensin-converting enzyme inhibitor group (p < 0.001
161 lood lactate was significantly higher in the angiotensin-converting enzyme inhibitor group than in th
162 ume withdrawn was significantly lower in the angiotensin-converting enzyme inhibitor group than in th
166 5), beta-blockers (HR = 0.5, p = 0.023), and angiotensin-converting enzyme inhibitors (HR = 0.6, p =
167 giotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors (HR, 1.33; 95%
168 ant (HOE-140) immediately before anesthesia (angiotensin-converting enzyme inhibitors + icatibant), a
169 n, clopidogrel, beta-blocker, statin, and an angiotensin-converting enzyme inhibitor in patients with
170 nist-neprilysin inhibitor was superior to an angiotensin-converting enzyme inhibitor in reducing mort
171 s support the need to reevaluate the role of angiotensin-converting enzyme inhibitors in humans with
172 val, which is a testament to the efficacy of angiotensin-converting enzyme inhibitors in renal crisis
173 sfunction (LVSD) suggest marginal benefit of angiotensin-converting enzyme inhibitors in the preventi
174 s a metabolite significantly associated with angiotensin-converting-enzyme inhibitors in our metabolo
175 d administration of quinapril, a long-acting angiotensin-converting enzyme inhibitor, in the manageme
176 ioedema, hereditary angioedema type III, and angiotensin converting enzyme inhibitor-induced angioede
177 II and III), acquired C1-INH deficiency, and angiotensin-converting enzyme inhibitor-induced angioede
179 alcium antagonist (amlodipine; n = 8174), an angiotensin-converting enzyme inhibitor (lisinopril; n =
180 get (95/60 to 110/75 mm Hg) and to either an angiotensin-converting-enzyme inhibitor (lisinopril) plu
181 erior compared with the 24-h BP reduction of angiotensin-converting enzyme inhibitors (mean BP reduct
182 harmacologic therapy that includes either an angiotensin-converting enzyme inhibitor (moderate-qualit
183 nsin II type 1 receptor antagonists (n=6) or angiotensin-converting enzyme inhibitors (n=6) exhibited
184 patients more often received beta-blockers, angiotensin-converting enzyme inhibitors, nitrates, and
186 e, primary renal disease classification, and angiotensin converting enzyme inhibitor or angiotensin r
187 tes mellitus and overt nephropathy receiving angiotensin converting enzyme inhibitor or angiotensin r
188 rat models of programming, administration of angiotensin converting enzyme inhibitors or angiotensin
189 the renin-angiotensin system with either an angiotensin-converting enzyme inhibitor or a mineralocor
190 without diabetes who are currently taking an angiotensin-converting enzyme inhibitor or an angiotensi
191 -angiotensin-aldosterone pathway, such as an angiotensin-converting enzyme inhibitor or an angiotensi
192 ack patients and 18.2% of patients not on an angiotensin-converting enzyme inhibitor or angiotensin I
193 (<140 mm Hg systolic, <90 mm Hg diastolic), angiotensin-converting enzyme inhibitor or angiotensin r
194 d as prescription of beta-blocker and either angiotensin-converting enzyme inhibitor or angiotensin r
195 l or add-on antihypertensive therapy with an angiotensin-converting enzyme inhibitor or angiotensin r
196 ssociation (NYHA) classification, and use of angiotensin-converting enzyme inhibitor or angiotensin r
198 ection fraction (93.4% versus 88.8%), use of angiotensin-converting enzyme inhibitor or angiotensin r
201 ith symptomatic decreased LVEF, 67% received angiotensin-converting enzyme inhibitor or angiotensin r
202 th asymptomatic decreased LVEF, 31% received angiotensin-converting enzyme inhibitor or angiotensin r
203 with reduced early mortality risk, and only angiotensin-converting enzyme inhibitor or angiotensin r
204 ance measures, aside from prescription of an angiotensin-converting enzyme inhibitor or angiotensin r
205 oup had worse baseline renal function, lower angiotensin-converting enzyme inhibitor or angiotensin r
206 every 1, 2, 5, or 10 years, with subsequent angiotensin-converting enzyme inhibitor or beta-blocker
207 estin 2, but not in MFS mice treated with an angiotensin-converting enzyme inhibitor or lacking angio
209 atory profile, and were less likely to be on angiotensin-converting enzyme inhibitors or aldosterone
210 0.017) but not among those only treated with angiotensin-converting enzyme inhibitors or angiotensin
212 e of antihypertensive medications other than angiotensin-converting enzyme inhibitors or angiotensin
214 re, where use of beta-blockers, statins, and angiotensin-converting enzyme inhibitors or angiotensin
215 95% CI, 0.75-0.99; P = 0.030) and trends for angiotensin-converting enzyme inhibitors or angiotensin
216 ng diuretics (95.9%), beta-blockers (82.5%), angiotensin-converting enzyme inhibitors or angiotensin
217 R, 4.17; [95% CI, 1.42-12.23]; P=0.009), and angiotensin-converting enzyme inhibitors or angiotensin
218 microalbuminuria followed by treatment with angiotensin-converting enzyme inhibitors or angiotensin
219 were receiving insulin, and 84% were taking angiotensin-converting enzyme inhibitors or angiotensin
220 79) and the following discharge medications: angiotensin-converting enzyme inhibitors or angiotensin
221 h above 10 cm (p = 0.023), no treatment with angiotensin-converting enzyme inhibitors or angiotensin
223 ends in the uptake of key medical therapies (angiotensin-converting enzyme inhibitors or angiotensin
226 ng full coverage for aspirin, beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin
227 opathy and proteinuria >1 g/d, maintained on angiotensin-converting enzyme inhibitors or angiotensin
228 ck patients and patients with intolerance to angiotensin-converting enzyme inhibitors or angiotensin
229 elet P2Y12 receptor inhibitors, statins, and angiotensin-converting enzyme inhibitors or angiotensin
230 bing, indications, and contraindications for angiotensin-converting enzyme inhibitors or angiotensin
231 vention medications (statins, beta-blockers, angiotensin-converting enzyme inhibitors or angiotensin
232 giotensin-aldosterone system with the use of angiotensin-converting enzyme inhibitors or angiotensin
233 ary discharge diagnosis of HF, initiation of angiotensin-converting enzyme inhibitors or angiotensin
234 ose eligible at discharge were not receiving angiotensin-converting enzyme inhibitors or angiotensin
235 and 88% were receiving beta-blockers and 81% angiotensin-converting enzyme inhibitors or angiotensin
237 sting), prescribing appropriate medications (angiotensin-converting enzyme inhibitors or angiotensin-
238 giotensin system (RAS) blockade therapy with angiotensin-converting enzyme inhibitors or angiotensin-
240 sting), prescribing appropriate medications (angiotensin-converting enzyme inhibitors or angiotensin-
241 th literacy and less likely to be prescribed angiotensin-converting enzyme inhibitors or beta-blocker
242 between angiotensin II receptor blockers and angiotensin-converting enzyme inhibitors or between diur
243 al data but no human data demonstrating that angiotensin-converting enzyme inhibitors or losartan, an
245 , K+ > or =5.0 mmol/l, and background use of angiotensin-converting enzyme inhibitors or spironolacto
246 300 mg daily) or placebo as an adjunct to an angiotensin-converting-enzyme inhibitor or an angiotensi
248 erent statins, a calcium-channel blocker, an angiotensin-converting enzyme inhibitor, or an acyl coen
249 ary coverage for all statins, beta-blockers, angiotensin-converting enzyme inhibitors, or angiotensin
250 ss might be modulated by the use of statins, angiotensin-converting enzyme inhibitors, or glucocortic
251 10 patients) for all statins, beta-blockers, angiotensin-converting-enzyme inhibitors, or angiotensin
252 Her medications include a beta-blocker, angiotensin-converting enzyme inhibitor, oral antidiabet
253 marital status, and baseline beta-blockers, angiotensin-converting enzyme inhibitors, oral anticoagu
254 g proportion of days covered for statins and angiotensin-converting enzyme inhibitors, patients were
255 As predicted, BALB/c mice pretreated with angiotensin-converting enzyme inhibitors potentiated IFN
257 can-American race was associated with higher angiotensin-converting enzyme inhibitor prescription and
258 blockers, angiotensin receptor blockers, and angiotensin-converting enzyme inhibitors; prophylactic s
259 no evidence at present to support the use of angiotensin-converting enzyme inhibitors prophylacticall
261 s indicated that angiotensin II (Ang II) and angiotensin converting enzyme inhibitors regulated blood
263 roglobulin is active, that the complex is an angiotensin-converting enzyme inhibitor-resistant reserv
264 hereas 91% and 54% were on beta-blockers and angiotensin-converting enzyme inhibitors, respectively.
266 ption of antiplatelet agents, beta-blockers, angiotensin-converting enzyme inhibitor, statins at disc
268 purpura nephritis, recent data indicate that angiotensin converting enzyme inhibitor therapy is indic
269 of renal function, and hyperkalemia than was angiotensin-converting enzyme inhibitor therapy alone.
270 treatment of avascular necrosis, and use of angiotensin-converting enzyme inhibitor therapy for micr
272 ia could identify patients with COPD in whom angiotensin-converting enzyme inhibitor therapy improves
273 effectiveness of sacubitril-valsartan versus angiotensin-converting enzyme inhibitor therapy in patie
274 hod to follow the immunomodulatory impact of angiotensin-converting enzyme inhibitor therapy on myelo
275 who derive significant clinical benefit from angiotensin-converting enzyme inhibitor therapy regardle
277 lled in the PEACE (Prevention of Events With Angiotensin-Converting Enzyme Inhibitor Therapy) trial.
280 er the study period (beta-blockers, statins, angiotensin-converting enzyme inhibitors, thienopyridine
281 tensin Receptor-Neprilysin Inhibitor With an Angiotensin-Converting Enzyme Inhibitor to Determine Imp
282 re use was high, ranging from 78% for use of angiotensin-converting enzyme inhibitors to 96% for use
283 in-receptor-neprilysin inhibitor) with ACEI (angiotensin-converting enzyme inhibitor) to Determine Im
284 in Receptor-Neprilysin Inhibitor] With ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Im
285 in Receptor-Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Im
286 in Receptor-Neprilysin Inhibitor] with ACEI [Angiotensin-Converting-Enzyme Inhibitor] to Determine Im
287 a randomized placebo-controlled trial of the angiotensin-converting enzyme inhibitor trandolapril.
288 eceptor blockade during hemorrhagic shock in angiotensin-converting enzyme inhibitor-treated mice.
290 nuates the deleterious hemodynamic effect of angiotensin-converting enzyme inhibitor treatment in mic
291 resent findings support the possibility that angiotensin-converting enzyme inhibitor treatment might
293 with HF; however, retrospective analysis of angiotensin-converting enzyme inhibitor trials and prosp
294 sure, and no angiotensin II receptor blocker/angiotensin-converting enzyme inhibitor use were associa
295 body mass index, diabetes, hypertension, and angiotensin-converting enzyme inhibitor use, BB intake w
297 n, other lipid-lowering agents, aspirin, and angiotensin-converting enzyme inhibitors was identified.
298 The benefit of sacubitril/valsartan, over an angiotensin-converting enzyme inhibitor, was consistent
299 renergic receptor blocker (beta-blocker) and angiotensin converting enzyme inhibitor, which were comm
300 m, as evidenced by trials that have compared angiotensin-converting enzyme inhibitors with drugs that
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。